Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancer with MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-world overall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. Results: 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n = 55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1 months. Among radiation-naive patients on 1L capmatinib (n = 20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1 months. Conclusion: This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients. Tweetable abstractWe evaluated #realworld outcomes for patients with #NSCLC with METex14 mutation and brain metastases, treated with capmatinib in clinical practice. We found substantial systemic and intracranial effectiveness with first-line capmatinib therapy.

Automated summary

This study aimed to assess the real-world clinical outcomes of MET exon 14 skipping mutation NSCLC patients with brain metastases who received capmatinib in routine US clinical practice. The results showed substantial effectiveness of capmatinib in both systemic and intracranial treatment, especially in first-line therapy and radiation-naive patients. These findings demonstrate the potential of capmatinib as a promising treatment option for this subgroup of patients.